NCT04579640

Trial of Vitamin D to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections

Phase 3 Randomised Controlled Trial of Vitamin D Supplementation to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections in the UK Population

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 6,200 (actual)
• Sponsor: Queen Mary University of London · Academic / Other
• Sex: All
• Age: 16 Years
• Healthy volunteers: Accepted

Summary

CORONAVIT is an open-label, phase 3, randomised clinical trial testing whether implementation of a test-and-treat approach to correction of sub-optimal vitamin D status results in reduced risk and/or severity of COVID-19 and other acute respiratory infections.

Conditions

• Covid19
• Acute Respiratory Tract Infection

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Vitamin D	Capsules containing 800 IU (20 micrograms) or 3,200 IU (80 micrograms) cholecalciferol

Timeline

• Start date: 2020-10-27
• Primary completion: 2021-06-17
• Completion: 2022-02-28
• First posted: 2020-10-08
• Last updated: 2022-04-06

Locations

1 site across 1 country: United Kingdom